Powered by: Motilal Oswal
2025-12-07 05:32:20 pm | Source: Prabhudas Lilladher Capital
Buy Max Financial Services Ltd For Target Rs.1,925 by Prabhudas Liladhar Capital Ltd
Buy Max Financial Services Ltd For Target Rs.1,925 by Prabhudas Liladhar Capital Ltd

Growth to sustain; margin outlook favorable

We met with the management of Axis Max Life to identify key drivers of growth and margin outlook over the medium-term. Company expects tailwinds from strong protection growth in H2 and has launched new products across PAR/ NPAR and annuity to drive growth. It expects agency/ e-commerce channel and new banca partners to sustain growth momentum over the medium-term. While FY26E VNB Margin is likely to see a drag from GST exemption due to nonavailability of ITC, it expects re-balancing of product mix (towards NPAR/ protection) and cost optimization initiatives to absorb the hit. We build a positive margin profile - 24.2%/ 24.6% for FY26/ FY27E as the share of NPAR/ protection improves. We value Max Life using the Appraisal Value framework with a TP of Rs1,925 (2.1x FY27E P/EV vs. 2.0 earlier). Strong outlook on growth and margin trajectory to be key positives. Retain BUY.

* Multiple levers to sustain growth momentum: 2QFY26 APE grew 15% YoY driven by protection and NPAR and company expects the momentum to continue to H2. It expects near-term tailwinds in retail protection volume post GST exemption and expects a recovery in credit life disbursals to drive growth. Newly launched products - Smart VIBE (NPAR), SWAG 2.0 (PAR) and SWAG Pension (Annuity) are seeing strong traction and are expected to offset the de-growth in ULIP (-9% YoY in Q2). Over the medium-term, company expects to maintain a diversified product mix with ~35% in ULIP, 15%/ 25% in PAR/ NPAR, 10-15% in protection and 5-7% in annuity. We build an APE growth of 16% CAGR over FY25-28E driven by robust growth in protection and new launches across PAR/ NPAR/ annuity.

* Proprietary and new banca partners to drive growth: Proprietary channel (+22% YoY) contributed 46% of APE in Q2 and constitutes agency, direct and e-commerce. Company has recruited new 64k agents since FY22 and is now looking at productivity levers to drive higher growth from the channel. Within e-commerce, Axis Max Life has been ranked #1 in online protection and recently launched savings business and expects to maintain the position. Within banca, it has tied up with new partners- South Indian bank, Ujiivan SFB, Tamil Nadu Mercantile Bank, CSB and DCB and already has the highest counter-share in 3 out of the 6 new banks. Post re-branding, company has identified verticals within Axis Bank (Bharat banking, credit card segment, D2C) to get exclusive leads/ access to customers and has dedicated manpower (~7k employees) across Axis Bank branches. Company has 65-70% counter-share within Axis Bank and expects to maintain it at a similar level over the medium-term. While Axis Bank as a channel has grown 12% over FY20-25, it expects new banca partners/ proprietary channel to grow faster. Company has also started selling via brokers in FY23 and expects the channel to contribute to growth.

* VNB Margin to range between 24- 25%: The company highlighted a negative gross impact of ~300-350bps on FY26E VNB margin due to non-availability of Input Tax Credit. However, it is undertaking various measures such as distributor re-negotiations, cost optimization/ efficiency initiatives such as cut in discretionary expenses (consulting, professional, legal, travel) to offset the impact. Moreover, strong growth in protection/ NPAR in H2 is likely to absorb the hit from GST exemption. H1FY26 VNB Margin stood at 23.3% and the company reiterated a guidance of 24-25%, considering the drag from GST exemption. We build a margin of 24.2%/ 24.6% for FY26/ FY27E, driven by a favorable product mix.

* Awaiting reverse merger guidelines: Company expects the Insurance Bill to be passed in the Winter/ Budget session of Parliament, with a clear timeline for its reverse merger with Max Financial. On composite licenses, it is in discussion with health insurance companies to distribute retail health. It expects IFRS-17 to be applicable over the next 2 years and has submitted proforma statements to IRDAI for easier implementation.

 

 

Please refer disclaimer at https://www.plindia.com/disclaimer/

SEBI Registration No. INH000000271

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here